Gabapentin Tablet
Product Images NDC 50090-7715

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-7715). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 01)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 01)
Chemical structure of gabapentin, a compound featuring a cyclohexane ring with an amino group and carboxylic acid group attached to the same carbon.*
FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 02)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 02)
A line graph comparing mean pain scores over eight weeks between placebo and Gabapentin 3600 mg/day. The x-axis shows weeks, including baseline, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, with Gabapentin scores decreasing more over time than placebo.*
FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 03)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 03)
A line graph showing mean pain scores over a 7-week period, comparing placebo with Gabapentin dosed at 1800 mg/day and 2400 mg/day. The x-axis represents weeks from baseline, divided into a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, with pain scores decreasing over time for both Gabapentin doses compared to placebo.*
FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 04)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 04)
A bar chart showing the proportion of responders (patients with ≥ 50% reduction in pain score) at endpoint from two controlled PHN studies. Study 1 compares placebo (PBO) at 12% to Gabapentin (GBP) 3600 mg at 29%. Study 2 shows placebo at 14%, Gabapentin 1800 mg at 32%, and Gabapentin 2400 mg at 34%, with statistical significance indicated for Gabapentin groups.*
FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 05)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 05)
A scatter plot chart showing percentage difference on the vertical axis versus daily dose in mg on the horizontal axis, with data points labeled for three studies (a, b, and c). Different colored squares represent STUDY a, STUDY b, and STUDY c, with doses ranging from 600 mg to 1800 mg.*
FDA Label Image

Label Image (Lbl500907715)

Label Image (Lbl500907715)
Gabapentin 600 mg oral tablets packaging label from A-S Medication Solutions. The label states each tablet contains 600 mg of gabapentin, with storage instructions at 77 degrees Fahrenheit. It indicates a package count of 90 tablets and includes the NDC 50090-7715.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.